Jenna Ellis
Manager
Expertise:
Jenna is a Manager on the Value & Evidence team at EVERSANA with experience conducting indirect treatment comparisons.
Since joining the team in 2022, Jenna has been involved in the development and execution of several indirect treatment comparisons including methods such as network meta-analysis, penalized likelihood network meta-analysis, multilevel network meta-regression, matching-adjusted indirect comparison, and simulated treatment comparison.
Jenna is well-versed in evidence synthesis. Prior to joining EVERSANA, she was part of a research team responsible for one of the largest systematic reviews in the Cochrane library and has also conducted meta-epidemiological research on the quality of trials used in evidence synthesis.
Jenna holds an MSc in Epidemiology specializing in Biostatistics from Queen’s University.
Articles by Jenna Ellis
Comparing First-Line Treatments for mCRPC: Insights From a Comprehensive NMA
Several first-line (1L) pharmacological treatments are available for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), an incurable condition with poor prognosis and quality of life. Benefits to patient survival in clinical trials have been demonstrated for many 1L mCRPC treatments, including novel agents such as talazoparib plus enzalutamide. However, due to the lack of direct comparisons, it is unclear how new treatments compare to many of those already used in clinical practice, creating challenges when choosing which therapeutic option to recommend to patients. To help bridge this gap, Elena Castro, MD; the team at Pfizer Inc. (Alexander Niyazov and Jonathan Nazari); and the Value & Evidence team […]
Filling in the Gaps: Predicting Treatment Effects From Surrogate Endpoints
Over the past 15 years, the treatment landscape for first-line metastatic castration-resistant prostate cancer (mCRPC) has undergone significant changes, marked by the approval and investigation of several new therapies. With multiple pharmacological treatments available for first-line mCRPC, network meta-analyses (NMAs) can serve as a valuable resource for evaluating clinical effectiveness that reflects current and local clinical practice. Recent clinical guidelines emphasize the importance of standardized reporting and evaluation of clinical trial outcomes in response to the rapidly evolving treatment landscape. However, older trials evaluating relevant treatments may lack certain outcome data, posing challenges when comparing them with recent trials designed to meet current guidelines through NMAs. Advanced statistical methods are […]